Impact of hiv infection on the course of ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Impact of hiv infection on the course of inflammatory bowel disease and drug safety profile: a multicenter getaid study
Auteur(s) :
Guillo, Lucas [Auteur]
Uzzan, Mathieu [Auteur]
Beaugerie, Laurent [Auteur]
Gornet, Jean-Marc [Auteur]
Amiot, Aurelien [Auteur]
Pelletier, Anne-Laure [Auteur]
Altwegg, Romain [Auteur]
Laharie, David [Auteur]
Abitbol, Vered [Auteur]
Filippi, Jerome [Auteur]
Goutorbe, Felix [Auteur]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Nancey, Stéphane [Auteur]
Viennot, Stéphanie [Auteur]
Reenaers, Catherine [Auteur]
Amil, Morgane [Auteur]
Caillo, Ludovic [Auteur]
Buisson, Anthony [Auteur]
Collins, Michael [Auteur]
Picon, Laurence [Auteur]
Vidon, Mathias [Auteur]
Benezech, Alban [Auteur]
Rabaud, Christian [Auteur]
Baumann, Cedric [Auteur]
Rousseau, Helene [Auteur]
Dubourg, Gregory [Auteur]
Serrero, Melanie [Auteur]
Peyrin-Biroulet, Laurent [Auteur]
Uzzan, Mathieu [Auteur]
Beaugerie, Laurent [Auteur]
Gornet, Jean-Marc [Auteur]
Amiot, Aurelien [Auteur]
Pelletier, Anne-Laure [Auteur]
Altwegg, Romain [Auteur]
Laharie, David [Auteur]
Abitbol, Vered [Auteur]
Filippi, Jerome [Auteur]
Goutorbe, Felix [Auteur]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Nancey, Stéphane [Auteur]
Viennot, Stéphanie [Auteur]
Reenaers, Catherine [Auteur]
Amil, Morgane [Auteur]
Caillo, Ludovic [Auteur]
Buisson, Anthony [Auteur]
Collins, Michael [Auteur]
Picon, Laurence [Auteur]
Vidon, Mathias [Auteur]
Benezech, Alban [Auteur]
Rabaud, Christian [Auteur]
Baumann, Cedric [Auteur]
Rousseau, Helene [Auteur]
Dubourg, Gregory [Auteur]
Serrero, Melanie [Auteur]
Peyrin-Biroulet, Laurent [Auteur]
Titre de la revue :
Clinical gastroenterology and hepatology . the official clinical practice journal of the American Gastroenterological Association
Nom court de la revue :
Clin Gastroenterol Hepatol
Date de publication :
2020-12-24
ISSN :
1542-7714
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
OBJECTIVE: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is ...
Lire la suite >OBJECTIVE: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown. METHODS: We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients. RESULTS: Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p = 0.012 for UC) and biologics (p = 0.004 for CD and p = 0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p = 0.45) and UC (HR, 1.1 [0.5; 2.7], p = 0.767). The overall drug safety profile was statistically similar between the two groups. CONCLUSIONS: Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.Lire moins >
Lire la suite >OBJECTIVE: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown. METHODS: We conducted a multicenter retrospective cohort study between January 2019 and August 2020. All adult patients with IBD and concomitant HIV infection were included. Each IBD patient with HIV was matched to two HIV-uninfected IBD patients. RESULTS: Overall, 195 patients with IBD were included, including 65 HIV-infected patients and 130 without HIV infection. Of the 65 infected patients, 22 (33.8%) required immunosuppressants and 31 (47.7%) biologics. In the HIV-infected group, the need for immunosuppressants (p = 0.034 for CD and p = 0.012 for UC) and biologics (p = 0.004 for CD and p = 0.008 for UC) was significantly lower. The disease course, using a severity composite criterion, was not significantly different between the two groups for CD (hazard ration (HR) = 1.3 [0.7; 2.4], p = 0.45) and UC (HR, 1.1 [0.5; 2.7], p = 0.767). The overall drug safety profile was statistically similar between the two groups. CONCLUSIONS: Although HIV-infected patients receive less treatments, the course of their IBD did not differ than uninfected, suggesting that HIV infection might attenuate IBD. The drug safety profile is reassuring, allowing physician to treat these patients according to current recommendations.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:44:54Z